clinical trial · NCT04367675
INO 5401 Vaccination in BRCA1/2 Mutation Carriers
BRCA1/2 MutationINO-5401INO-9012Cellectra 2000
brief summary
The research study is being conducted to test an experimental vaccine to potentially prevent cancer for people with BRCA1 or BRCA2 mutations. This study will test if the vaccine is safe (without significant side effects) and test a new way of administering vaccines. It will also test whether the vaccine activates your immune system.
started
Apr 20, 2021
primary completion
Dec 1, 2026
completion
Mar 1, 2027
last updated
Oct 21, 2026
official title
Phase 1b Study of INO-5401 Alone or INO-5401 in Combination With INO-9012 Followed by Electroporation in Adult Cancer and Non-Cancer Patients With BRCA1 or BRCA2 Mutations
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol